Gliofocus – Phase 3 Study of Niraparib for Glioblastoma
  • August 8, 2024
The Gliofocus Study is a global, open-label, randomized Phase 3 clinical trial sponsored by the Ivy Brain Tumor Center that will compare the efficacy of niraparib, a PARP1/2-selective inhibitor, versus temozolomide in adult patients with newly diagnosed MGMT unmethylated glioblastoma. 
Learn More
Temsirolimus in Recurrent High-Grade Glioma
  • January 17, 2023
A Phase 0 dose-escalation study using superselective intra-arterial cerebral infusion of temsirolimus for the treatment of recurrent high-grade glioma. 
Learn More